A phase II trial with sorafenib, an inhibitor targeting BRAF, VEGFR, PDGFR and c-kit was terminated due to unexpected acceleration of tumor growth, which was not dependent on NF1 status [75]. The gene discussed is NF1; the disease is neoplasm.